Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells

Journal of Proteome Research

Volumn 12, Issue 7, 2013, Pages 3264-3276

  Paulitschke, Verena ^a   Haudek Prinz, Verena ^b,c   Griss, Johannes ^a,b   Berger, Walter ^b   Mohr, Thomas ^b   Pehamberger, Hubert ^a   Kunstfeld, Rainer ^a   Gerner, Christopher ^b,c  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

bioinformatics; drug resistance; mass spectrometry; melanoma; proteomics

Indexed keywords

CALCIUM ION; CELL ADHESION MOLECULE; CISPLATIN; PROTEOME; SECRETOME; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CYTOPLASM; HUMAN; HUMAN CELL; LYSOSOME; MASS SPECTROMETRY; MELANOMA; PRIORITY JOURNAL; PROTEIN BINDING;

CELL LINE, TUMOR; CISPLATIN; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; MASS SPECTROMETRY; MELANOMA; NEOPLASM PROTEINS; PROTEOMICS; TRANSCRIPTOME;

EID: 84879897801     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr400124w     Document Type: Article

References (47)

1. Sinha, P.; Poland, J.; Kohl, S.; Schnolzer, M.; Helmbach, H.; Hutter, G.; Lage, H.; Schadendorf, D. Study of the development of chemoresistance in melanoma cell lines using proteome analysis Electrophoresis 2003, 24 (14) 2386-404
2. Hodgkinson, V. C.; Eagle, G. L.; Drew, P. J.; Lind, M. J.; Cawkwell, L., Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status. Cancer Lett 294, (1), 13-24.
3. Bundscherer, A.; Reichle, A.; Hafner, C.; Meyer, S.; Vogt, T. Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists Anticancer Agents Med Chem 2009, 9 (7) 816-21
4. Paulitschke, V.; Kunstfeld, R.; Mohr, T.; Slany, A.; Micksche, M.; Drach, J.; Zielinski, C.; Pehamberger, H.; Gerner, C. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: Secretome analysis of associated stroma cells J Proteome Res 2009, 8 (5) 2501-10
5. Li, S. L.; Ye, F.; Cai, W. J.; Hu, H. D.; Hu, P.; Ren, H.; Zhu, F. F.; Zhang, D. Z., Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J. Cell Biochem. 109, (4), 625-33.
6. Meijerman, I.; Beijnen, J. H.; Schellens, J. H. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer Cancer Treat. Rev. 2008, 34 (6) 505-20
7. Zehender, H.; Mayr, L. M. Application of mass spectrometry technologies for the discovery of low-molecular weight modulators of enzymes and protein-protein interactions Curr. Opin. Chem. Biol. 2007, 11 (5) 511-7
8. Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Muller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 2009, 23 (3) 477-85
9. Rix, U.; Hantschel, O.; Durnberger, G.; Remsing Rix, L. L.; Planyavsky, M.; Fernbach, N. V.; Kaupe, I.; Bennett, K. L.; Valent, P.; Colinge, J.; Kocher, T.; Superti-Furga, G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 2007, 110 (12) 4055-63
10. Bantscheff, M.; Boesche, M.; Eberhard, D.; Matthieson, T.; Sweetman, G.; Kuster, B. Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer Mol. Cell Proteomics 2008, 7 (9) 1702-13
11. Bantscheff, M.; Hopf, C.; Kruse, U.; Drewes, G. Proteomics-based strategies in kinase drug discovery Ernst Schering Found. Symp. Proc. 2007, 3, 1-28
12. Smith, M. P.; Wood, S. L.; Zougman, A.; Ho, J. T.; Peng, J.; Jackson, D.; Cairns, D. A.; Lewington, A. J.; Selby, P. J.; Banks, R. E. A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses Proteomics 2011, 11 (11) 2222-35
13. Yan, X. D.; Pan, L. Y.; Yuan, Y.; Lang, J. H.; Mao, N. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines J. Proteome Res. 2007, 6 (2) 772-80
14. Gong, F.; Peng, X.; Zeng, Z.; Yu, M.; Zhao, Y.; Tong, A., Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method. Mol. Cell. Biochem. 348, (1-2), 141-7.
15. D'Aguanno, S.; D'Alessandro, A.; Pieroni, L.; Roveri, A.; Zaccarin, M.; Marzano, V.; De Canio, M.; Bernardini, S.; Federici, G.; Urbani, A. New insights into neuroblastoma cisplatin resistance: A comparative proteomic and meta-mining investigation J. Proteome Res. 2011, 10 (2) 416-28
16. Castagna, A.; Antonioli, P.; Astner, H.; Hamdan, M.; Righetti, S. C.; Perego, P.; Zunino, F.; Righetti, P. G. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431 Proteomics 2004, 4 (10) 3246-67
17. Stewart, J. J.; White, J. T.; Yan, X.; Collins, S.; Drescher, C. W.; Urban, N. D.; Hood, L.; Lin, B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels Mol. Cell Proteomics 2006, 5 (3) 433-43
18. Sansing, H. A.; Sarkeshik, A.; Yates, J. R.; Patel, V.; Gutkind, J. S.; Yamada, K. M.; Berrier, A. L., Integrin alphabeta1, alphavbeta, alpha6beta effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. Biochem. Biophys. Res. Commun. 406, (2), 171-6.
19. Gerner, C.; Frohwein, U.; Gotzmann, J.; Bayer, E.; Gelbmann, D.; Bursch, W.; Schulte-Hermann, R. The Fas-induced apoptosis analyzed by high throughput proteome analysis J. Biol. Chem. 2000, 275 (50) 39018-26
20. Mueller, B. M.; Romerdahl, C. A.; Trent, J. M.; Reisfeld, R. A. Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor Cancer Res. 1991, 51 (8) 2193-8
21. Hynes, R. O. Integrins: Versatility, modulation, and signaling in cell adhesion Cell 1992, 69 (1) 11-25
22. Haudek-Prinz, V. J.; Klepeisz, P.; Slany, A.; Griss, J.; Meshcheryakova, A.; Paulitschke, V.; Mitulovic, G.; Stockl, J.; Gerner, C. Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells J Proteomics 2012, 10.1016/j.jprot.2012.07.012
23. Mortz, E.; Krogh, T. N.; Vorum, H.; Gorg, A. Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis Proteomics 2001, 1 (11) 1359-63
24. Slany, A.; Haudek, V. J.; Gundacker, N. C.; Griss, J.; Mohr, T.; Wimmer, H.; Eisenbauer, M.; Elbling, L.; Gerner, C. Introducing a new parameter for quality control of proteome profiles: Consideration of commonly expressed proteins Electrophoresis 2009, 30 (8) 1306-28
25. Nesvizhskii, A. I.; Keller, A.; Kolker, E.; Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry Anal. Chem. 2003, 75 (17) 4646-58
26. Ishihama, Y.; Oda, Y.; Tabata, T.; Sato, T.; Nagasu, T.; Rappsilber, J.; Mann, M. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein Mol. Cell Proteomics 2005, 4 (9) 1265-72
27. Helmbach, H.; Rossmann, E.; Kern, M. A.; Schadendorf, D. Drug-resistance in human melanoma Int. J. Cancer 2001, 93 (5) 617-22
28. Siddik, Z. H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance Oncogene 2003, 22 (47) 7265-79
29. Brozovic, A.; Ambriovic-Ristov, A.; Osmak, M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin Crit. Rev. Toxicol. 2010, 40 (4) 347-59
30. Wen, J.; Zheng, B.; Hu, Y.; Zhang, X.; Yang, H.; Li, Y.; Zhang, C. Y.; Luo, K. J.; Zang, X.; Li, Y. F.; Guan, X. Y.; Fu, J. H., Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int. J. Oncol. 36, (1), 265-74.
31. Jones, P.; Cote, R. G.; Martens, L.; Quinn, A. F.; Taylor, C. F.; Derache, W.; Hermjakob, H.; Apweiler, R. PRIDE: A public repository of protein and peptide identifications for the proteomics community Nucleic Acids Res. 2006, 34 (Database issue) D659-63
32. Martens, L.; Hermjakob, H.; Jones, P.; Adamski, M.; Taylor, C.; States, D.; Gevaert, K.; Vandekerckhove, J.; Apweiler, R. PRIDE: The proteomics identifications database Proteomics 2005, 5 (13) 3537-45
33. Griss, J.; Haudek-Prinz, V.; Gerner, C. GPDE: A biological proteomic database for biomarker discovery and evaluation Proteomics 2011, 11 (5) 1000-4
34. Ashburner, M.; Ball, C. A.; Blake, J. A.; Botstein, D.; Butler, H.; Cherry, J. M.; Davis, A. P.; Dolinski, K.; Dwight, S. S.; Eppig, J. T.; Harris, M. A.; Hill, D. P.; Issel-Tarver, L.; Kasarskis, A.; Lewis, S.; Matese, J. C.; Richardson, J. E.; Ringwald, M.; Rubin, G. M.; Sherlock, G. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium Nat. Genet. 2000, 25 (1) 25-9
35. Chauhan, S. S.; Liang, X. J.; Su, A. W.; Pai-Panandiker, A.; Shen, D. W.; Hanover, J. A.; Gottesman, M. M. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines Br. J. Cancer 2003, 88 (8) 1327-34
36. Alao, J. P.; Sunnerhagen, P. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation Radiat.. Oncol 2009, 4, 51
37. Hamai, A.; Meslin, F.; Benlalam, H.; Jalil, A.; Mehrpour, M.; Faure, F.; Lecluse, Y.; Vielh, P.; Avril, M. F.; Robert, C.; Chouaib, S. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway Cancer Res. 2008, 68 (23) 9854-64
38. Schmidmaier, R.; Morsdorf, K.; Baumann, P.; Emmerich, B.; Meinhardt, G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo Int. J. Biol. Markers 2006, 21 (4) 218-22
39. Khodadoust, M. S.; Verhaegen, M.; Kappes, F.; Riveiro-Falkenbach, E.; Cigudosa, J. C.; Kim, D. S.; Chinnaiyan, A. M.; Markovitz, D. M.; Soengas, M. S. Melanoma proliferation and chemoresistance controlled by the DEK oncogene Cancer Res. 2009, 69 (16) 6405-13
40. Bradbury, P. A.; Middleton, M. R. DNA repair pathways in drug resistance in melanoma Anticancer Drugs 2004, 15 (5) 421-6
41. Boyle, G. M. Therapy for metastatic melanoma: An overview and update Expert Rev. Anticancer Ther. 2011, 11 (5) 725-37
42. Ooe, A.; Kato, K.; Noguchi, S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers Breast Cancer Res Treat 2007, 101 (3) 305-15
43. Johnson, J. P. Cell adhesion molecules in the development and progression of malignant melanoma Cancer Metastasis Rev. 1999, 18 (3) 345-57
44. Secchiero, P.; Voltan, R.; di Iasio, M. G.; Melloni, E.; Tiribelli, M.; Zauli, G. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells Clin. Cancer Res. 2010, 16 (6) 1824-33
45. Satyamoorthy, K.; Bogenrieder, T.; Herlyn, M. No longer a molecular black box-New clues to apoptosis and drug resistance in melanoma Trends Mol. Med. 2001, 7 (5) 191-4
46. Soengas, M. S.; Capodieci, P.; Polsky, D.; Mora, J.; Esteller, M.; Opitz-Araya, X.; McCombie, R.; Herman, J. G.; Gerald, W. L.; Lazebnik, Y. A.; Cordon-Cardo, C.; Lowe, S. W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma Nature 2001, 409 (6817) 207-11
47. Kim, J. W.; Nie, B.; Sahm, H.; Brown, D. P.; Tegeler, T.; You, J. S.; Wang, M. Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2010, 878 (7-8) 700-4